Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “buy” rating reiterated by equities researchers at Numis Securities Ltd in a report issued on Thursday. They currently have a GBX 2,350 ($29.11) price objective on the stock. Numis Securities Ltd’s target price points to a potential upside of 33.22% from the stock’s current price.

Several other research analysts have also recently weighed in on HIK. Morgan Stanley initiated coverage on Hikma Pharmaceuticals Plc in a research report on Thursday, July 21st. They set an “equal weight” rating and a GBX 2,700 ($33.44) price objective on the stock. Jefferies Group increased their price objective on Hikma Pharmaceuticals Plc from GBX 2,800 ($34.68) to GBX 2,990 ($37.04) and gave the stock a “buy” rating in a research report on Tuesday, July 26th. Barclays PLC reiterated an “overweight” rating and set a GBX 2,800 ($34.68) price objective on shares of Hikma Pharmaceuticals Plc in a research report on Thursday, August 4th. JPMorgan Chase & Co. lowered their price objective on Hikma Pharmaceuticals Plc from GBX 2,800 ($34.68) to GBX 2,550 ($31.59) and set an “overweight” rating on the stock in a research report on Thursday, August 4th. Finally, Citigroup Inc. cut Hikma Pharmaceuticals Plc to a “neutral” rating and set a GBX 2,600 ($32.21) price objective on the stock. in a research report on Thursday, August 4th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of GBX 2,489.90 ($30.84).

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Shares of Hikma Pharmaceuticals Plc (LON:HIK) opened at 1725.00 on Thursday. The company’s market capitalization is GBX 3.90 billion. Hikma Pharmaceuticals Plc has a one year low of GBX 1,575.00 and a one year high of GBX 2,703.00. The firm’s 50-day moving average price is GBX 1,937.41 and its 200 day moving average price is GBX 2,217.78.

In related news, insider Al-Husry,Ali bought 140,000 shares of Hikma Pharmaceuticals Plc stock in a transaction dated Wednesday, August 31st. The shares were bought at an average cost of GBX 2,150 ($26.63) per share, with a total value of £3,010,000 ($3,728,477.64). Also, insider Said Darwazah bought 10,000 shares of Hikma Pharmaceuticals Plc stock in a transaction dated Wednesday, September 28th. The shares were bought at an average cost of GBX 2,085 ($25.83) per share, for a total transaction of £208,500 ($258,268.30).

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.

Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.